Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

Antimicrob Agents Chemother. 1992 Jul;36(7):1559-62. doi: 10.1128/AAC.36.7.1559.

Abstract

The combination of zidovudine (AZT) and 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro with AZT-sensitive and AZT-resistant clinical isolates and HIV-1IIIB. Synergy was determined by the median-effect principle and isobologram techniques. Cytotoxicity of the agents was not observed. Clinical trials are ongoing to define the combination's role in HIV-1 therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Drug Combinations
  • Drug Synergism
  • HIV-1 / drug effects*
  • Humans
  • Virus Replication / drug effects
  • Zalcitabine / pharmacology*
  • Zidovudine / pharmacology*

Substances

  • Drug Combinations
  • Zidovudine
  • Zalcitabine